Mitsui Chemicals to Expand Production Capacity of LUCANT™
Mitsui Chemicals, Inc. (TOKYO:4183)(President & CEO: Tsutomu Tannowa) announced the decision to construct a new plant for the production of LUCANT™, hydrocarbon-based synthetic fluid, at its Ichihara Works in response to the expansion of global demand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180823005209/en/
LUCANT(TM) (Photo: Business Wire)
|
[Outline of New plant] |
||
| 1. Product | Hydrocarbon-based synthetic oil | |
| 2. Brand Name | LUCANT ™ | |
| 3. Location | Ichihara Works of Mitsui chemicals | |
| 4. Production Capacity | 20,000ton/year | |
| 5. Schedule | Commercial operations : February 2021 | |
LUCANT™ is a high performance, hydrocarbon-based, specialty synthetic fluid used primarily as a viscosity modifier. It is used in the most demanding applications including automotive driveline, industrial lubricants and greases, and is the approved choice for leading OEMs and global oil marketers. Mitsui Chemicals was the first manufacturer to offer to the market this unique synthetic fluid which boasts industry leading efficiency and durability.
The investment in additional LUCANT™ capacity will allow us to meet the
evolving and demanding needs of the Lubricant market.
Mitsui
Chemicals has decided to strengthen our production capacity for LUCANT™
in order to secure a stable supply capability and drive its business
growth.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180823005209/en/
Contact information
Mitsui Chemicals, Inc.
Takashi Kawamoto, +81-3-6253-2100
Corporate
Communications Division
takashi.kawamoto@mitsuichemicals.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Logitech Announces Q4 and Full Fiscal Year 2025 Results29.4.2025 23:03:00 EEST | Press release
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2025 ended March 31, 2025. For Fiscal Year 2025: Sales were $4.55 billion, up 6 percent in US dollars and 7 percent in constant currency, compared to the prior year. GAAP operating income was $655 million, up 11 percent compared to the prior year. Non-GAAP operating income was $775 million, up 11 percent compared to the prior year. GAAP earnings per share (EPS) was $4.13, up 7 percent compared to the prior year. Non-GAAP EPS was $4.84, up 14 percent compared to the prior year. Cash flow from operations was $843 million. The year-ending cash balance was $1.5 billion. The Company returned $797 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2025: Sales were $1.01 billion, flat in US dollars and up 2 percent in constant currency, compared
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene29.4.2025 22:32:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent, in response to a patent infringement lawsuit Pharmacyclics brought against BeiGene concerning BRUKINSA® (zanubrutinib). On May 1, 2024, the USPTO granted BeiGene’s petition to institute the PGR. The USPTO’s Final Written Decision is appealable by Pharmacyclics. Commenting on the ruling, BeiGene General Counsel Chan Lee said: “We are pleased that the USPTO invalidated all challenged claims of the ‘803 patent. Today’s decision reinforces our belief th
One out of Three Secure Civil IDs Delivered Each Year Is Powered by Thales29.4.2025 17:50:00 EEST | Press release
Each year, Thales powers one in three smart civil IDs (official electronic documents) issued worldwide, highlighting the company’s key role in shaping the future of identities and helping governments and citizens transition smoothly to digital. With its Civil Identity Suite, Thalesenables the issuance and management of both physical and digital identities, as well as all means of enrolling citizens and enabling seamless ID verification for access to services, both in-person and online. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429687137/en/ Thales Civil Id Suite (Photo: Thales Shutterstock) Thales, a global leader in advanced technologies and #1 global leader in ID documents, has recently earned the new title of #1 provider of Digital ID solutions as recognized by Juniper Research (2024). With unmatched experience and scale, Thales empowers governments to modernise their identity systems, ensuring they meet the deman
Andersen Global Enhances European Valuation Capabilities through Collaboration with Value & Risk Valuation Services29.4.2025 16:30:00 EEST | Press release
Andersen Global continues to strengthen its valuation capabilities through a Collaboration Agreement with Value & Risk Valuation Services, a prominent European valuation firm headquartered in Germany with offices in Luxembourg and Austria. Founded in 1996, Value & Risk Valuation Services is a management-owned firm specializing in the valuation of financial assets across diverse asset classes and varying complexities. The firm also provides complementary services, including independent price verification (IPV), risk analysis, and transaction cost analysis. Since 2009, the company has been led by Gil Bender, who is dedicated to delivering high-quality, client-centric valuation solutions. As one of the few European providers offering external valuation services in compliance with the European Alternative Investment Fund Managers Directive (AIFMD), Value & Risk upholds the highest industry standards for regulatory compliance and service excellence. “Since our inception, we have focused on
Solving Border Control Staffing Challenges: Regula Launches an Ecosystem for Remote Document Examination29.4.2025 16:00:00 EEST | Press release
Regula, a global developer of forensic devices and identity verification solutions, introduces an innovative solution designed to transform document examination processes, particularly in border control operations. Based on high-resolution photospectral scanners from the Regula 88XX product line, it enables highly accurate and reliable remote document authentication, effectively addressing the pressing issue of staffing shortages in border security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429852027/en/ High-resolution photospectral scanner Regula 8880 for remote document verification (Photo: Regula) Traditionally, document authenticity experts needed to be physically present at each checkpoint. However, this requirement has become increasingly challenging due to current staffing constraints. For example, a recent European Commission report highlights gaps in the availability of certain specialized experts, notably
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom